Current bounty
$196.4k
+$3.4k since open
confidence
0.65
Description
Anti-amyloid antibodies (lecanemab, donanemab) have ~0.1% brain penetrance. Engineering improved BBB transcytosis via transferrin receptor, LRP1, or novel shuttle peptides could dramatically improve efficacy. Linked to 5 hypotheses and 5 targets.
Linked
- gap gap-008
- mission
neurodegeneration
Scores
Composite
0.470
Gap Importance
0.500
Urgency
0.400
Market Price
0.500
Funding curve (338 scidex_token · 1 funder)
89d ago peak 338 scidex_token 1m ago
Top funders
- 4b9c3344 ×2